Life Expectancy and Survival Analysis of Patients with Diabetes Compared to the Non Diabetic Population in Bulgaria
Overview
Authors
Affiliations
Aims: To evaluate the expected life expectancy in patients with diabetes in Bulgaria and to compare it to the expected life expectancy of the non-diabetic population in the country.
Methods: It is a retrospective observational population study on individuals diagnosed with diabetes, compared to the non-diabetic population in Bulgaria for the period 2012-2015. Data from the national diabetes register and national statistical institute were used to construct life-tables with probability of survival with t-test and Chi Square test. Confounder analysis was done by age, sex, and type of diabetes. All-cause mortality and deaths in diabetic patients were analyzed. Kaplan-Meier survival curves were constructed for each age group and a log-rank analysis was conducted.
Results: Average life expectancy in the non-diabetic population, patients with Type 1 DM and with Type 2 DM is 74.8; 70.96 and 75.19 years, respectively. For 2012-2015 the mortality in the non-diabetic population remained constant and lower (average-1.48%) compared to type-1 DM (5.25%) and Type-2 (4.27%). Relative risk of death in diabetics was higher overall (12%), after the age of 70 before which the relative risk was higher for the non-diabetic population. This was observed as a trend in all analyzed years.
Conclusion: Patients with type 2 DM have a longer life-expectancy than patients with type-1 DM and overall Diabetics life expectancy equals that of the non-diabetic population, which could suggest improved disease control and its associated complications in Bulgaria. Male diabetics show slightly longer life expectancy than their counterparts in the non-diabetic population, by a marginal gain of 0.6 years for the entire observed period. Life expectancy in diabetic women increased by 1.3 years, which was not observed in the non-diabetic population. Prevalence of diabetes was higher for women. Improved diabetes control may explain this gain in life; however other studies are needed to confirm this.
Mitkova Z, Stanimirova D, Manova M, Gerasimov N, Mitov K, Petrova G Healthcare (Basel). 2025; 13(3).
PMID: 39942512 PMC: 11817434. DOI: 10.3390/healthcare13030322.
Alawaji R, Musslem M, Alshalahi E, Alanzan A, Sufyani A, Alhati M Diabetol Metab Syndr. 2024; 16(1):224.
PMID: 39267155 PMC: 11391676. DOI: 10.1186/s13098-024-01459-w.
Nishimura A, Masuda C, Murauchi C, Ishii M, Murata Y, Kawasaki T Drugs Aging. 2024; 41(6):531-542.
PMID: 38795310 PMC: 11193829. DOI: 10.1007/s40266-024-01119-8.
Sharma P, Dilip T, Kulkarni A, Mishra U, Shejul Y BMC Public Health. 2024; 24(1):1048.
PMID: 38622601 PMC: 11020643. DOI: 10.1186/s12889-024-18465-2.
Caiazzo G, Oliva A, Testa L, Heang T, Lee C, Milazzo D Cardiovasc Diabetol. 2024; 23(1):52.
PMID: 38310281 PMC: 10838457. DOI: 10.1186/s12933-024-02139-9.